DETECTION OF BCR ABL RNA TRANSCRIPTS USING THE POLYMERASE CHAIN-REACTION IS HIGHLY PREDICTIVE FOR RELAPSE IN PATIENTS TRANSPLANTED WITH UNRELATED MARROW GRAFTS FOR CHRONIC MYELOGENOUS LEUKEMIA/
Wr. Drobyski et al., DETECTION OF BCR ABL RNA TRANSCRIPTS USING THE POLYMERASE CHAIN-REACTION IS HIGHLY PREDICTIVE FOR RELAPSE IN PATIENTS TRANSPLANTED WITH UNRELATED MARROW GRAFTS FOR CHRONIC MYELOGENOUS LEUKEMIA/, British Journal of Haematology, 98(2), 1997, pp. 458-466
Relapse after allogeneic bone marrow transplantation (BMT) for chronic
myelogenous leukaemia (CML) is thought to result from residual leukae
mia cells which survive the intensive conditioning regimen and are not
eradicated by donor-derived immune effector cells capable of mediatin
g a graft-versus-leukaemia (GVL) effect. Early relapse can be detected
using highly sensitive assays such as the polymerase chain reaction (
PCR) which have been shown to have predictive value for subsequent rel
apse in selected patient populations. The validity of PCR for predicti
ng CML relapse in unrelated marrow transplant recipients where the GVL
effect appears to be augmented due to increased HLA disparity between
donor and recipient, however, has not been well defined. In this stud
y we assessed the prognostic value of PCR in a cohort of 52 patients t
ransplanted with T-cell-depleted unrelated marrow grafts for CML, The
actual probability of relapse at 3 years was 71% in patients with at l
east one positive assay versus 6% in patients with no positive assays
post-transplant. Patients with one or more positive assays at any time
post-transplant had a 56-fold increased risk of relapse which was sig
nificantly higher (P=0.0002) than that observed in patients who remain
ed persistently PCR negative, Moreover, PCR detected relapse a median
of 5 months earlier than cytogenetic analysis in a subgroup of patient
s in whom concurrent sampling had been performed, These data validate
the use of PCR as a prognostic test in this patient population and may
help to identify a cohort of patients to be considered as candidates
for pre-emptive adoptive immunotherapy.